Medrio’s Post

If you are a pioneering #biotech, #medicaldevice, or #diagnostics company, great insights in this month's Medrio Resource Roundup, including: - Thoughts on selecting technology to serve small teams and to extend your cash runway - Insight into the types of #clinicalresearch technologies that other #lifesciences companies are using as they evolve into #earlyphase trials

To run a successful oncology development program under the FDA's Project Optimus, it's crucial to focus on identifying the optimal dose range for your asset. In our latest blog, James Matcham and Mike Fossler provide valuable insights into Project Optimus and discuss key factors that can enhance your chances of success. Read the full article: https://bit.ly/3W8e2Dc #FDAProjectOptimus #FDA #Oncology #oncologydevelopment #clinicaltrials #optimaldose #drugdevelopment #pharma #biotech

With oncology research, the clock is always ticking. This is why many oncology clinical trials use master protocols and other innovative designs. Learn how eClinical Solutions helped one leading biopharma company deliver flexibility throughout the life of a study and efficiently manage and implement changes, reducing risk of costly delays. Read the full case study: https://lnkd.in/efXuMive #casestudy #biopharma #lifesciences #oncologyresearch #biometricsservices #clinicaltrials

🎥 Access the Recording: Early-Phase Oncology Trials Webinar Learn how small and emerging biopharma are driving oncology drug development in this insightful webinar. Discover key strategies from Avance Clinical and other industry leaders on optimizing early-phase oncology trials and navigating the complexities of drug development. 🌟 Gain insights into how experienced CROs support trial success, from patient recruitment to regulatory alignment. Watch the full recording here: https://lnkd.in/gGZ4Rarf #OncologyTrials #ClinicalTrials #Biotech #DrugDevelopment #Webinar #AvanceClinical

Solid tumors are a massive challenge for CAR-T - until now? "The first documented complete response in a patient with a solid tumour treated with CAR-T therapy" was reported by AffyImmune Therapeutics. This all came out as part of the deluge of ASCO (American Society of Clinical Oncology) abstracts that were unveiled last week. It's a Phase 1 so we're not popping the champagne yet - but it's a step in the right direction! Article and more deets in the comments below ⬇️ —————————— Comprehensive, daily coverage of the biotech and pharma industry, straight to your inbox (and all in one email) - that's TLDR Biotech. 🧬🔔 #biotech #pharma #pharmanews #biotechnews #tldrbiotech

Have you seen the announcement about our expanded Biosimilar partnership with #mAbxience? Partnerships are driving significant advantages in the Biosimilar space including accelerated development timelines, expanded market reach, cost optimization, and more diverse portfolios. As we continue to see these strategic partnerships unfold, it's clear that collaboration is key to advancing the biosimilars field. By working together, companies like #tevapharm and #mAbxience can overcome challenges, drive innovation, and ultimately improve patient outcomes. What's a better outcome than that? What are your thoughts on these alliance partnerships? How do you see them shaping the future of healthcare? Let's discuss in the comments below!#Biosimilars #StrategicPartnerships #Healthcare #Innovation #PatientAccess #TevaNexter https://lnkd.in/ebhbHCaS

Setting realistic expectations for how payer coverage is likely to build over time is critical for pharma companies. https://ow.ly/UAB250SjbFW In this case study, learn how one small oncology biopharma used MMIT’s coverage uptake analysis for new drugs to prepare for the launch of its therapy. #FDA #Oncology #Biopharma #BiopharmaInsights #MarketAccess

🎗 Explore our robust library of oncology learning content. Pharmaceutical companies rely on our trusted Oncology: Treatment and Management and Oncology Business Acumen curriculums to train their teams. In response to the rise of precision medicine, we've also introduced three new eModules on Precision Medicine. Equip your client-facing teams with the latest knowledge and skills needed to excel in the evolving field of oncology. Chat with our training experts to learn more. https://lnkd.in/dZmk7bbP #CMRInstitute #yourCMR #lifesciences #healthcare #lifescienceindustry #healthcareindustry #healthcareeducation #oncology #precisionmedicine

The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB

ESG401, a novel Trop2 ADC with SN38 conjugated to a humanized Trop2 mAb via a proprietary stable-cleavable linker at DAR8, is being evaluated in a Phase Ia/Ib ESG401-101 study to assess its efficacy in various subtypes of mBC in China. The results from this trial were presented at the ESMO - European Society for Medical Oncology 2024 conference. Maximize Your Knowledge with Expert Insights and Detailed Analysis through DelveInsight Business Research LLP's ESMO - European Society for Medical Oncology 2024 Exclusive Coverage @ https://lnkd.in/gRN_hK7Y #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical